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Radiation therapy is a core modality of cancer treatment; however, concerns have been expressed regarding its under-
utilization and its lack of prioritization as a research domain relative to other cancer treatment modalities, despite its
rapid technical evolution. It is therefore important to understand, from a public policy perspective, the evolution of
global radiation therapy research, to identify strengths, weaknesses, and opportunities. This study used a bibliometric
approach to undertake a quantitative analysis of global radiation therapy research published between 2001 and 2015
and available in the Web of Science (Wos) database, with particular focus on the 25 leading research-active countries.
A total of 62,550 radiation therapy research articles from 127 countries, published in 2531 international journals, were
analyzed. The United States was responsible for 32.3% of these outputs, followed by Japan (8.0%) and Germany (7.7%).
Nearly half of all publications related to preparation and delivery of radiation therapy, combined-modality regimens, and
dose fractionation studies. Health services research, palliative care, and quality of life studies represented only 2%, 5%,
and 4% of all research outputs, respectively. Countries varied significantly in their commitment to different research
domains, and trial-related publications represented only 5.1% of total output. Research impact was analyzed according
to 3 different citation scores, with research outputs from Denmark, The Netherlands, and the United States consistently
the highest ranked. Globally, radiation therapy publication outputs continue to increase but lag behind other spheres of
cancer management. The types of radiation therapy research undertaken appear to be regionally patterned, and there is a
clear disconcordance between the volume of research output from individual countries and its citation impact. Greater
support for radiation therapy research in low- and middle-income countries is required, including international collab-
oration. The study findings are expected to provide the requisite knowledge to guide future radiation therapy research
programs.  2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Reprint requests to: Ajay Aggarwal, MD, FRCR, PhD, Guy’s & St
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Aggarwal et al. International Journal of Radiation Oncology  Biology  Physics768Introduction and the citation impact of radiation therapy research stratifiedCancer research is one of the most globally active domains
of science, with more than $14 billion per annum in public
and private expenditure (1). Research is integral to
improving outcomes from cancer, be it through an
improved understanding of the etiology of disease, identi-
fying new treatment targets or modalities, or by the pro-
vision of information on how best to coordinate cancer
services to deliver affordable and equitable cancer care.
Radiation therapy is one of the main modalities of
control, cure, and palliation for cancer, with approximately
50% of cancer patients requiring radiation therapy during
their disease course (2-4). Given the outcomes it can deliver
with respect to survival and quality of life, its under-
utilization as a clinical modality (3) and the lack of prior-
itization it has been given as a research domain within the
cancer spectrum remain major concerns. A recent study
within lung cancer has found that only 8% of lung cancer
research is devoted to radiation therapy research, compared
with 20% for genetics, 17% for systemic therapies, and
16% for prognostic biomarkers (5). This undoubtedly will
influence patterns of care for particular disease entities and
the potential for new developments that will ultimately
improve patient outcomes.
It is therefore important to understand from a public
policy perspective how, why, and which particular research
domains evolve and have an impact on outcomes. For
example, how do different countries influence the radiation
therapy research agenda, either through the volume of
research they publish, the citation impact of their articles,
or their commitment to particular research domains (eg,
basic science, health services research)?
An empirical analysis of research outputs would also
highlight gaps and provide direction as to which research
areas should be prioritized to meet current and future
challenges. For example, there is currently an ongoing
debate (6) as to whether the increasing focus on techno-
logical innovation within radiation therapy to improve the
therapeutic ratio has been at the cost of not developing a
greater understanding of the potential role for radiation
therapy in exploiting cancer weaknesses based on the bio-
logical hallmarks of cancer. It is thought that further
research into these areas could unlock new and more cost-
effective opportunities for radiation therapy to improve
outcomes from cancer. In addition, it would help to ensure
that radiation therapy continues to be relevant and that
research in this area is prioritized in an era of precision
medicine, which is increasingly drug-focused (7, 8).
Using a bibliometric approach, we present an analysis of
global research on cancer radiation therapy between 2001 and
2015. This type of analysis is now used routinely in public
policy analysis to study research domains (9, 10). We examine
the growth in research output from 25 leading countries, the
volume of research produced relative to their wealth, the main
radiation therapy research domains these countries prioritize,according to country and research domain.
Methods and Materials
We performed a bibliometric analysis of radiation therapy
research outputs during 2001-2015, based on articles and
reviews in the Web of Science (WoS) database. This con-
tains full bibliographic information about the articles,
including all addresses as well as the numbers of citations
received by each article in each year. Of note, the use of
additional biomedical databases does not significantly in-
crease the yield of relevant journals.
We used filters (macro algorithms based on logic functions)
developed by an expert bibliometrician (G.L.) in conjunction
with the team’s expertise in radiation therapy and radiation
research to identify relevant articles in theWoS. The search for
radiation therapy articles included articles in ANY journal,
including general medical and basic science journals, provided
that they had a title term indicative of cancer (composed of 323
words and short phrases (11)) AND had the word “radiation or
radiotherapy” includingwildcard “rad*,”ORcontained 1 of the
12 radiation therapyespecific title words, such as “brachy-
therapy” (SupplementaryAppendix 1; available online atwww.
redjournal.org). It also included articles in 7 specialist cancer
radiation therapy journals identified by the study authors
(Supplementary Appendix 1; available online at www.
redjournal.org) and in 185 specialist cancer journals, provided
that articles in the latter contained 1 of the radiation therapy
filter terms. In addition, there were 20 more journals identified
by the authors that also covered both cancer and noncancer
radiation topics (Supplementary Appendix 1; available online
atwww.redjournal.org).Articles in these journalswere retained
ONLY if they had one of the 323 cancer filter terms.
All these filters were developed through iterative rounds,
which involved creating datasets and having these manually
coded by clinical experts as to their relevance to the
research fields being sought (using methods previously
described (12)). This process resulted in both a precision or
specificity and a recall or sensitivity for identifying radia-
tion therapy research articles of 0.95, which is considered
very high (11).
There were 127 countries that contributed to these ra-
diation therapy articles. However, the results presented in
this study will primarily focus on the 25 leading research-
active countries that are responsible for 97% of the total.
The counts of the numbers of publications per year were
obtained as both integer and fractional counts using the
article’s addresses. For example, if an article has 2 ad-
dresses in Germany and 1 in France it would be counted as
1 for each on an integer count basis, but as 0.67 and 0.33,
respectively, on a fractional count basis. Fractional counts
sum to less than the total partly because of the outputs of
the other countries and partly because some articles had no
addresses. Integer counts summed to more than the total
because of international co-authorship. Unless otherwise
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which give a much better impression than integer counts of
the relative research effort by each country (13, 14).Volume of research
For each of the 25 leading countries, we analyzed the numbers
of published radiation therapy research articles for each year
from 2001 to 2015 and calculated the annual average percent-
age growth rate (AAPG) and the ratio of outputs between 2011-
2015and2001-2005.Wealso calculated the commitment of the
25countries to radiation therapy research relative to their output
of cancer research overall. For example, between 2001 and
2015, Canada published 3956 articles out of a world total of
62,550 (6.3%). In the same period, Canada contributed to 4.2%
of all oncology research outputs worldwide. Canada’s relative
commitment to radiation therapy research was therefore 6.3/
4.2Z 1.50. For selected high- andmiddle-income countrieswe
also analyzed the association between radiation therapy
research output and each country’s gross domestic product
(GDP).TheGDP is ameasure of a country’s economyand is the
totalmarket value of all consumer goods and services produced
by all the people and companies in the country in a period of
time (quarterly or yearly).Radiation therapy research domains
Radiation therapy research publications were categorized
into 10 research domains. These were defined using sub-
filters that contained a set of title words and strings to
categorize relevant articles into particular domains. These
subfilters were all developed as part of an iterative process
by A.A. and Y.L. in collaboration with G.L., with additional
terms being added to each of the sufilters to capture many
of the articles not yet classified. We also used a complex
logic process as the individual subfilters were applied to the
spreadsheet, so that some articles were classified if they
were identified by particular subfilters but NOT by others.
The research domains and individual codes used for analysis
were as follows: BIOL ((radio)biology); PHYS (physics);
ASSU (quality assurance); FRAC (dose fractionation and
sequencing studies); COMB (multimodality studies involving
radiation therapy); PRED(preparation anddelivery of radiation
therapy); PALL (palliative care);QUAL(quality of life);HESR
(health services research); andREVS (review articles). Of note,
the PRED domain also included studies evaluating particle
therapy in the clinical setting. The domains were not mutually
exclusive, and therefore articles reviewing quality of life in
relation to clinical dose fractionation studieswould be included
in both categories (ie, QUAL and FRAC). In addition, articles
classified solely within either BIOL, PHYS, or ASSU were
treated as nonclinical basic science studies. The PRED, FRAC,
and COMB domains included studies that measured clinical
endpoints such as morbidity. Eventually, all but 6465 articles
were classified into 1 or more of these categories (10.3%).Fractional counts were calculated for each country and
research type, and the results compared with the world
totals so as to show whether a country was over- or un-
derrepresented relative to the world average for each
research domain. We also analyzed the number of articles
describing radiation therapy trials (phases 1-4) and the
fractional counts of these articles for each country.Citation impact by country and research domain
The citation counts for each article from 2001-2011, year
by year, were downloaded from the WoS. The 5-year
citation counts (actual citation impact, ACI) beginning in
the publication year were calculated. A 5-year window was
used as a compromise between the need for immediacy (ie,
citations to recent articles) and stability (ie, inclusion of the
peak year for citations, usually the second or third year
after publication). It is best determined for a country on the
basis of fractional counts, because many of the most cited
articles are multinational. Altogether, citation counts were
determined for 32,162 articles.
For each country we calculated an arithmetic mean cita-
tion score as a measure of the impact of their radiation
therapyerelated research. Thiswas based on theACI of each of
their articles during the study period. To calculate this, the
citation score for each article was multiplied by the country’s
fractional contribution to that article and the products summed,
and the total divided by the sum of the country’s fractional
counts for the relevant years. For example, for Germany, the
top-cited article, with 1360 citations, had a German presence
among the addresses of 0.133. Germanywas therefore credited
with 1360  0.1333 Z 181.3 citations. All the products for
individual articles were summed, to give the fractional German
citation total of 44,341.4 citations, which when divided by the
German fractional count citable total of 3306.9 articles gives an
arithmetic mean citation score of 13.41 citations per article. A
geometric mean was also calculated on the basis of the loga-
rithms of the actual citation counts. This value is considered to
be a better indicator because it is less influenced by a few very
high citation counts (15).
Another measure of citation impact is the number of a
country’s articles that receive enoughcitations toput them in the
top 1%, 2%, or 5%of all cited radiation therapy articles. During
the period of analysis (2001-2011), an articlewould have had to
receive 93, 68, and 44 citations, respectively, to be in these
centiles. AWorldScale (WS) value at a particular centile was
calculated according to the ratio of the proportion of articles
from a selected country in the top x%of cited articles compared
with theproportionof all articles in that particular centile. So for
Germany,with 3306.9 citable articles in the 11 years, because it
published 136.5 articles with 44 ormore citations, itsWS value
at 5%was (136.5/3306.9)/0.05 100Z83.This value is lower
than 100 and indicates it has fewer than the expected number of
articles in this centile. The 3WS values at 1%, 2%, and 5% for
each country were averaged to give a composite value for a
country’s highly cited articlesdthe WS mean.
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these 3 citation indicators (arithmetic, geometric, and WS
means), and the rankings were then averaged. Using similar
methods, we also determined the citation impacts for arti-
cles in the 10 research domains.
Finally, an analysis of the proportion of publications that
were open access between 2001 and 2015 was undertaken,
as well as a comparative analysis of 5-year citation scores
for open access versus noneopen access articles published
between 2010 and 2012.
Results
In total, 62,550 articles were identified from 2531 inter-
national journals and from 127 countries. Nearly all of the
articles were in English (60,494 articles, 96.7%), but others
were in 20 different languages, led by French (1193, 1.9%),
German (598, 0.96%), and Spanish (76, 0.12%). A few
were in Chinese, Japanese, or Korean.
The 25 leading research-active countries, which accoun-
ted for 96.9% (or 60,673 articles) of the total in the file,
included (in alphabetical order): Australia, Austria, Belgium,
Brazil, Canada, China, Denmark, France, Germany, Greece,
India, Iran, Italy, Japan, Netherlands, Norway, Poland, Re-
public of Korea, Spain, Sweden, Switzerland, Taiwan,
Turkey, the United Kingdom, and the United States.
Volume of research
Between 2001 and 2015 the volume of radiation therapy
research increased year on year, with a doubling in world
outputs (Fig. 1). The United States was responsible for
32.3% of these outputs (Table 1), followed by Japan (8.0%)
and Germany (7.7%). However, there have been significant
changes in the volume of research produced from some
countries, with Iran, China, Brazil, and South Korea0
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Fig. 1. Increase in radiation therapy research publicashowing the highest AAPG values and with output ratios
between 2011-2015 and 2001-2005 of 19.3, 10.4, 4.8, and
4.5, respectively.
Most countries had a smaller percentage presence in
radiation therapy research than they did in oncology overall
(Table 1). The Netherlands, Canada, and Belgium are
notable exceptions. China, despite having a sustained and
large increase in its volume of radiation therapy research
over the 15-year period, still had a smaller percentage
presence in radiation therapy research than in all cancer. A
similar pattern was observed for Brazil.
Figure 2 shows that thevolume of radiation therapy research
output is positively correlated with each country’s GDP, with
the spots for most of the selected high- and upper-middle-
income countries close to the least-squares regression line.
Notable exceptions areTheNetherlands,whichpublishedmore
than3 times asmuchas the regression linepredicts, andTaiwan,
Canada, and the United States, whose output was double or
almost double the amount predicted. On the other hand, upper-
middle-income countries, such as China and Brazil, published
less than half the predicted amounts. Russia published less than
one-tenth of the amount predicted from the regression line. All
these differences are highly statistically significant (P< .001%
on the Poisson distribution with 1 degree of freedom).
Research domains
Figure 3 shows the distribution of research articles during
the study period in 9 of the research domains. Clinical
research domains predominate, with studies focusing on (1)
preparation and delivery of radiation therapy (PRED, 24%),
(2) use of radiation therapy as part of combined modality
management (COMB, 17%), and (3) evaluation of different
dose fractionation schedules and sequencing of radiotherapy
(FRAC, 15%). These 3 domains accounted for nearly half of
all published radiation therapy research.2008 2009 2010 2011 2012 2013 2014 2015
Year
tion output between 2001 and 2015 (n Z 62,550).
Table 1 Outputs of radiation therapy articles from the world
and 25 leading countries, 2001-2015
Country All years % AAPG Ratio R.C.
Worldwide 62,550 6.2 1.87
United States 20,097 32.2 3.7 1.47 1.07
Japan 5019 8.0 5.4 1.75 0.92
Germany 4782 7.7 2.7 1.34 1.21
China 3122 5.0 23.3 10.4 0.53
United Kingdom 2986 4.8 3.1 1.39 0.92
Canada 2944 4.7 6.6 1.91 1.51
France 2931 4.7 8.9 2.35 1.09
Italy 2661 4.3 5.1 1.71 0.81
Netherlands 2448 3.9 5.5 1.74 1.69
Republic of Korea 2140 3.4 16.0 4.53 0.99
Australia 1464 2.3 11.5 3.14 1.13
Taiwan 923 1.5 10.5 2.64 0.78
Spain 879 1.4 9.9 2.64 0.65
India 855 1.4 11.9 3.14 0.73
Sweden 834 1.3 1.7 1.15 0.96
Belgium 823 1.3 4.0 1.47 1.45
Turkey 796 1.3 8.8 2.24 0.85
Switzerland 769 1.2 4.6 1.54 1.32
Denmark 541 0.9 11.1 3.01 1.21
Poland 497 0.8 9.6 2.57 0.78
Austria 486 0.8 1.2 0.90 1.14
Brazil 485 0.8 15.6 4.80 0.64
Greece 435 0.7 0.0 1.04 0.81
Norway 401 0.6 7.0 2.07 1.02
Iran 299 0.5 32.1 19.30 0.88
Abbreviations: % Z percentage of world output; AAPG Z annual
average percentage growth; Ratio Z output in 2011-2015/output in
2001-2005; R.C.Z relative commitment to radiation therapy research
compared to all cancer.
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Fig. 2. Outputs of radiation therapy research articles as a
function of national wealth (log-log scales). Diagonal line
is best power-law least-squares correlation line; dashed
lines show values twice and half those of the correlation
line. Abbreviations: ATZ Austria; AUZ Australia; BEZ
Belgium; BR Z Brazil; CA Z Canada; CH Z
Switzerland; CN Z China; CZ Z Czech Republic;
DE Z Germany; DK Z Denmark; ES Z Spain; FI Z
Finland; FRZ France; GRZ Greece; IEZ Ireland; ILZ
Israel; INZ India; IRZ Iran; ITZ Italy; JPZ Japan; KR
Z Republic of Korea; NL Z The Netherlands; NO Z
Norway; PL Z Poland; RS Z Russia; SE Z Sweden; SG
Z Singapore; TR Z Turkey; TW Z Taiwan; UK Z
United Kingdom; US Z United States.
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outputs, with radiobiological (BIOL) investigation ac-
counting for 19% and physics (PHYS) for 13% of total
outputs. Health services research (HESR) was very limited,
accounting for only 2% of the total. Palliative care (PALL)
and quality of life studies (QUAL) in radiation therapy also
made only small contributions to the literature, of 5% and
4%, respectively.
Figure 3 shows that between 2001-2005 and 2011-2015,
radiobiology research has had the most modest increase in
volume of research output (AAPG Z 4.8) compared with
clinical domains such as preparation and delivery
(AAPG Z 9.0) and dose fractionation studies
(AAPG Z 9.3). Health services research has had sustained
increases over the time period, with an AAPG of 10.8.
Table 2 shows the relative commitment of different
countries to the 9 research domains. Whereas the United
States, France, and Austria are well represented in all the
domains, this is not so for other countries. For example,
China’s radiation therapy research is focused on basic sci-
ence, particularly on radiobiology. Canada has a focus on
physics, palliative care, and health services research. The
Netherlands, Belgium, Denmark, and Iran have a strong
commitment to physics research, with The Netherlands alsonoticeable for its commitment to quality of lifeerelated
research and Iran to quality assurance. Australia, like Can-
ada, and to a lesser extent the United Kingdom, is notable for
its strong commitment to health services research; Norway
excels in quality of life and palliative care research.Clinical trial outputs
Of the 62,550 radiation therapy articles, only 3926
(6.3%) involved clinical trials. Of these, 34 described
preparatory work, and 687 were secondary sources
(meta-analyses, systematic reviews, and other trials
without specification of stage). The remaining 3205 ar-
ticles (5.1%) described trials in the 4 established phases:
769 phase 1, 1065 phase 2, 1367 phase 3, and 4 described
phase 4 trials. Table 3 demonstrates the variation in
clinical trial outputs across the top 20 leading countries.
The United States published the greatest number of
outputs across phase 1 to phase 3 studies. Japan is
notable for the high proportion of publications describing
phase 1 studies relative to all other countries. With
respect to phase 2 trial outputs, Japan again features
strongly, as does Italy and China. Phase 3 trial outputs
are dominated by the United Kingdom, Germany, and
The Netherlands after the United States. An analysis of
the ratio of phase 3 to phase 2 trial outputs from each of
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Fig. 3. Distribution of radiation therapy articles by research domain, 2001-2015, and annual average percentage growth
rates for the articles in the research domain. Abbreviations: ASSU Z quality assurance; BIOL Z (radio)biology;
COMB Z multimodality studies involving radiation therapy; FRAC Z dose fractionation and sequencing studies;
HESRZ health services research; PALLZ palliative care; PHYSZ physics; PREDZ preparation and delivery of radiation
therapy; QUAL Z quality of life.
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tion. The United States, for instance, had a relatively low
ratio of phase 3 relative to phase 2 outputs. This was also
notable for countries such as Japan (0.50), Italy (0.58),
Republic of Korea (0.60), and Spain (0.46). Conversely,
countries such as the United Kingdom (3.45),
Netherlands (4.72), Sweden (4.14), and Poland (5.02)
published more than double the number of trial outputs
of phase 3 studies compared with phase 2 studies in the
study period. India, a middle-income country, also had a
strong commitment to phase 3 studies (2.83).
Citation counts and research impact
Table 4 shows the 25 leading countries with their mean ACI
values (arithmetic and geometric) and their mean WS
values. The latter is based on the numbers of their articles
with enough citations to put them in the top 1% (93 ci-
tations), top 2% (68 citations), and top 5% (44 cita-
tions), as described in the Methods and Materials section.
The countries are ranked according to the mean ranking
across the 3 scales.
We find that Denmark, The Netherlands, the United
States, Switzerland, and Belgium are the only countries
with consistently superior performance at all 3 WS per-
centiles (ie, values > 100). High research output countries
such as China, Japan, and Germany rank in the lower half
of the table. Conversely, Denmark, Switzerland, and
Belgium seem to produce research with greater impact,
despite the low volume of their research relative to that of
the other countries.
Table 5 shows the citation impact of different radiation
therapy research domains according to the mean WS
values. It shows that whereas review articles, and researchfocusing on combined modality treatment (eg, radiation and
drug therapies), are highly cited and potentially will have a
greater impact on practices of care, research into quality
assurance and health services research may have less
impact, with a small fraction of articles in the top centiles
of cited radiation therapy articles.
Open access articles
Figure 4 presents a breakdown of the changing proportion
of radiation therapy research articles available through the
WoS that are closed (ie, behind a pay wall), gold open
access (all freely available from the publisher), or green
open access (available from the author’s archive). The
proportion of open access articles has continued to increase
since 2001. Green open access articles are the best cited:
the mean ACI for 2010-2012 articles was 19.7 citations in
5 years, compared with 15.7 citations for gold open access
and 12.3 citations for closed articles.Discussion
This analysis of the global research landscape is the first
to characterize the output of radiation therapy research
globally and to identify trends in research priorities and
contributions by individual countries. We found a
doubling in overall research output over a 15-year period,
consistent with trends observed in other disciplines (16).
The globalization of research has been a major contrib-
utor to this increase in output. Although the United
States was responsible for more than one-third of the
radiation therapy research output between 2001 and
2015, there was only a 55% increase in research output
Table 2 Relative commitment of leading 25 countries to different domains of radiation therapy research, 2001-15 (A color version of
this table is available at www.redjournal.org.)
Country Total PRED BIOL COMB FRAC PHYS ASSU PALL QUAL HESR
World 62,550 15,091 12,149 10,426 9406 7802 4444 3092 2579 1320
United States 20,097 1.11 0.94 0.90 0.92 0.99 0.96 0.89 0.96 1.08
Japan 5019 1.10 1.18 1.47 0.95 0.67 0.67 1.02 0.63 0.85
Germany 4782 1.02 1.23 0.84 1.03 0.95 0.72 1.41 1.22 0.78
China 3122 0.95 1.60 1.29 0.99 0.81 0.76 0.97 0.72 0.24
United Kingdom 2986 0.81 0.96 0.85 0.92 1.27 1.01 0.78 1.26 1.42
Canada 2944 0.97 0.78 0.62 0.87 1.47 1.19 1.73 1.15 2.05
France 2931 0.93 0.80 1.07 0.95 0.77 0.90 0.92 0.98 0.76
Italy 2661 1.02 0.72 1.35 1.70 0.88 1.26 1.09 0.95 0.85
Netherlands 2448 1.00 0.85 0.91 0.97 1.55 0.70 0.91 1.95 1.16
Republic of Korea 2140 0.94 1.18 1.54 1.45 0.65 0.78 1.12 0.40 0.20
Australia 1464 0.89 0.56 0.79 0.77 1.18 1.65 0.96 1.11 2.19
Taiwan 923 0.92 1.25 1.40 1.00 0.70 1.00 0.71 1.40 0.97
Spain 879 1.08 0.81 1.19 1.39 1.06 1.45 0.69 0.85 1.33
India 855 1.00 1.08 0.86 1.02 0.96 1.70 0.70 0.95 1.17
Sweden 834 0.59 1.40 0.45 0.95 1.24 1.08 0.44 1.57 1.45
Belgium 823 1.03 1.08 0.68 0.87 1.64 1.30 0.64 0.81 1.22
Turkey 796 0.72 0.64 1.31 1.17 0.68 0.70 1.57 1.22 0.25
Switzerland 769 1.39 0.79 0.86 1.01 1.20 1.11 0.90 0.59 1.03
Denmark 541 0.85 1.09 0.64 0.79 1.83 0.97 0.45 1.39 0.96
Poland 497 0.93 0.95 0.64 1.27 0.72 1.30 1.31 1.13 0.71
Austria 486 1.14 0.75 0.79 0.98 1.30 1.05 0.82 0.74 0.83
Brazil 485 0.85 0.71 1.15 1.05 0.67 2.07 0.51 0.89 0.86
Greece 435 0.58 0.95 1.44 1.14 1.61 1.62 1.24 0.79 0.16
Norway 401 0.52 1.54 0.82 0.79 0.77 0.58 2.52 2.33 1.16
Iran 299 0.46 1.11 0.57 0.34 2.05 3.28 0.60 0.77 0.32
Abbreviations: ASSU Z quality assurance; BIOL Z (Radio)biology; COMB Z multimodality studies involving radiation therapy; FRAC Z dose
fractionation and sequencing studies; HESRZ health services research; PALLZ palliative care; PHYSZ physics; PREDZ preparation and delivery of
radiation therapy; QUAL Z quality of life.
Notes: Cells with values > twice world average tinted bright green; those > 1.40  world average tinted pale green; those < 0.71  world average
tinted yellow; those < 0.51  world average tinted pink.
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more than 2000% in China.
Significant increases in research output were also seen in
several other middle-income countries, including India,
Brazil, Turkey, and Iran, although their overall contribution
to total worldwide radiation therapy research remained
small. In this regard, it is important to acknowledge the
issues related to access to radiation therapy in the majority
of low- and middle-income countries (LMICs) (17), which
undoubtedly will have important implications on their
ability to influence the research portfolio.
Furthermore, when these countries’ research output is
compared with their GDP, they still lag some way behind
the major high-income countries. This is likely to be
influenced by differences in cancer research funding be-
tween LMICs and high-income countries. We know that
only 2.7% of total global cancer research investment is
directly relevant to LMICs (18). Of that investment, the
majority of cancer research funding is directed to studiesthat focus on cancer biology and drug development, rather
than radiation therapyerelated research (5, 19).
It is important that LMICs are supported and encouraged
to participate in research because of the need to continue to
develop cost-effective treatment pathways, which can also
meet key goals such as equity and efficiency within the
constraints of their health system (20). The wider research
community will also benefit from a more globally inclusive
research base, given inherent differences in cancer epide-
miology and biology related to risk factor exposure. In the
European Union for instance, limitations in the size (by
population) and resources of individual countries is
compensated by strong international collaboration, with the
European Organization for Research and Treatment of
Cancer (EORTC) acting to coordinate radiation therapy
research in the region.
It may be argued that with improved survival outcomes
and more people living with cancer (21), there should be
greater attention in research to the domains of quality of
Table 3 Number of articles relating to phase 1, phase 2, and phase 3 radiation therapy trials published by the 20 leading countries
between 2001 and 2015
Country Phase 1 Phase 2 Phase 3
% of total phase 1
outputs* (n Z 769)
% of total phase 2
outputs* (n Z 1065)
% of total phase 3
outputs* (n Z 1367)
Ratio of phase 3
to phase 2 trial
outputsy
World 770 1066 1367
United States 329.5 349.6 287.6 42.8 32.8 21 0.82
Japan 108.1 98.1 48.9 14 9.2 3.6 0.50
Germany 48.2 47.3 106.9 6.3 4.4 7.8 2.26
China 31.6 61.8 75.6 4.1 5.8 5.5 1.22
United Kingdom 26.2 36.8 126.9 3.4 3.4 9.3 3.45
Canada 28.9 35.3 76.8 3.7 3.3 5.6 2.18
France 23 61 82.3 3 5.7 6 1.35
Italy 38.7 82.2 48 5 7.7 3.5 0.58
Netherlands 22.8 19.3 91.1 3 1.8 6.7 4.72
Republic of Korea 12.4 46.2 27.9 1.6 4.3 2 0.60
Australia 13.7 22.6 58 1.8 2.1 4.2 2.57
Taiwan 3 5.1 10.4 0.4 0.5 0.8 2.04
Spain 11 37.3 17 1.4 3.5 1.2 0.46
India 2.5 9.4 26.6 0.3 0.9 1.9 2.83
Sweden 3.6 8.8 36.4 0.5 0.8 2.7 4.14
Belgium 10 18.8 17.4 1.3 1.8 1.3 0.93
Turkey 0 6.1 10.1 0 0.6 0.7 1.66
Switzerland 12.7 13.4 16.7 1.7 1.3 1.2 1.25
Denmark 4.1 14.3 25 0.5 1.3 1.8 1.75
Poland 2.3 4.6 23.1 0.3 0.4 1.7 5.02
Number of articles expressed as fractional country counts.
* Percentage contribution of each individual country to total world phase 1, phase 2, and phase 3 research outputs.
y Ratio of articles describing phase 3 studies and phase 2 studies for each individual country.
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areas represent only 4%, 2%, and 5% of total radiation
therapy research outputs, respectively, over the study
period. This is in stark contrast to other clinical research
domains, such as preparation and delivery (24%) and dose
fractionation studies (15%). Quality of life research seems
particularly low given the dominance of clinical studies
involving patients and the importance of this as a clinical
endpoint.
This discrepancy between the health needs of the pop-
ulation and current research priorities was also found in
other cancer studies. In a bibliometric analysis, Sanson-
Fisher et al (22) found that there were 4 times as many
publications on chemotherapy in 2005 as on quality of life
research, despite steady increases in the latter over the
preceding 20 years.
Health services research encompasses a broad multi-
disciplinary area addressing issues related to access, eq-
uity, and the value of health care. This branch of research
helps to define new research priorities. It also aids
effective implementation and sustainability of new inno-
vative processes of care given the health system con-
straintsdfinancial, political, or geographicdof a
particular country. However, despite its importance, this
area of research still lags far behind more established
clinical and basic science research domains. It may not be
considered to have the same value or relevance as other
domains, as shown by its relatively low citation impact.Furthermore, this is an interdisciplinary subject area and
requires collaboration between radiation oncologists and
social scientists, such as health economists and
epidemiologists.
However, this view may finally be changing because of
growing fiscal constraints that affect both high-income
countries and LMICs and an increasing focus on value-
based frameworks within medicine (23, 24). One example
is the Health Economics in Radiation Oncology project
under the auspices of the European Society of Radiation
Oncology, which seeks to address the shortfall in applied
research in this area (25).
The low commitment of several countries to palliative
care research shown in Table 3 may be the result of the
relative lack of senior academic appointments in this
domain. This may limit opportunities for cross-sectoral
research collaboration and for the attraction of research
funding and the creation of research infrastructure (26).
Norway demonstrated the strongest commitment to pallia-
tive care research, relative to other priorities. This is likely
to reflect the country’s strong support for palliative care at
all levels of the public health care system (27).
The predominance of clinical research outputs in our
study is also a likely reflection of the particular time period
in which these analyses were undertaken, in which signif-
icant technical improvements have been made (intensity
modulated radiation therapy, particle therapy, motion
management) that have sought to reduce the morbidity
Table 4 Five-year citation performance of 25 leading countries in radiation therapy research, 2001-2011
Country Citable WS (ranking) Arithmetic (ranking) Geometric (ranking)
Denmark 301 199 (1) 19.8 (1) 11.8 (1)
Netherlands 1604 147 (3) 18.7 (2) 11.4 (2)
United States 13,572 154 (2) 17.2 (3) 9.8 (3)
Switzerland 512 131 (4) 16.7 (5) 9.5 (5)
Belgium 563 117 (5) 16.8 (4) 9.6 (4)
Canada 1922 101 (7) 14.7 (6) 8.4 (6)
United Kingdom 2045 100 (8Z) 14.2 (7) 7.8 (7)
Austria 355 93 (10) 13.4 (9Z) 7.2 (10)
World 39,657 100 (8Z) 13.7 (8) 7.3 (9)
Germany 3307 79 (12) 13.4 (9Z) 7.5 (8)
Australia 805 86 (11) 12.5 (11) 6.8 (13)
Sweden 571 74 (13) 11.9 (13) 7 (11)
France 1804 103 (6) 12.1 (12) 5.6 (17)
Norway 267 49 (17) 11.1 (14) 6.9 (12)
Italy 1690 57 (14Z) 10.6 (15) 5.3 (18)
China 1062 45 (18) 10.5 (16Z) 6.1 (15)
Republic of Korea 1135 30 (21) 10.5 (16Z) 6.3 (14)
Spain 513 57 (14Z) 9.1 (19) 4.6 (21)
Greece 326 40 (19Z) 8.6 (21) 4.8 (20)
Taiwan 538 9 (24) 9.4 (18) 6 (16)
Japan 3243 27 (22) 8.8 (20) 5.2 (19)
Brazil 265 40 (19Z) 7.6 (22) 4 (22)
Poland 302 50 (16) 7.1 (23) 3.1 (24)
India 508 13 (23) 5.4 (24) 3.3 (23)
Turkey 473 3 (25) 4.2 (25) 2.3 (25)
Iran 116 0 (26) 3.6 (26) 2.2 (26)
Abbreviation: WS Z WorldScale.
Citable Z numbers of articles in these years; WS Z WS mean value at top 1%, 2%, and 5% of citations; Arithmetic Z arithmetic mean of actual
citation impact values; Geometric Z geometric mean of actual citation impact values. Countries are ranked by mean ranking on these 3 indicators.
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in this era, such as those assessing multimodality therapy
(28) and different dose fractionation schedules (29), have
been a natural consequence of the preclinical research
performed in the 1980s and 1990s, which had a much
greater biological focus, with studies addressing dose per
fraction, hypoxia, and drugeradiation interactions.
Review articles were the most highly cited research
domain, which suggests that evidence syntheses in theTable 5 Presence of radiation therapy articles in the 10 research dom
mean WorldScale (WS) values
Domain Citable Top 5% Top 2% Top 1
REVS 2733 256 104 59
COMB 6435 452 227 135
FRAC 5650 344 154 88
PRED 8944 601 207 94
PALL 1758 96 36 17
BIOL 7975 470 159 71
PHYS 4708 252 88 32
QUAL 1611 84 29 11
HESR 727 26 10 3
ASSU 2660 71 18 8
Abbreviations as in Table 2.
Numbers of publications with 137 citations (top 1%), 86 citations (top 2%), 50
percentages of a country’s publications in the top x% (1%, 2%, and 5%) relative
100). Mean is average of WS values.form of systematic reviews and meta-analyses have the
potential to greatly influence practice, which is desirable.
Research into multimodality therapy involving radiation
therapy is also highly cited, most likely because of the
large investment made in such studies (especially those
involving pharmaceuticals) and the importance that these
outputs have across the entire cancer spectrum from
basic science to medical, surgical, and radiation
oncology.ains in the top citation centiles, and overall ranking on basis of
% WS 5% WS 2% WS 1% Mean
189 191 216 199
142 177 210 176
123 137 156 138
135 116 105 119
110 103 97 103
119 100 89 103
108 94 68 90
105 90 68 88
72 69 41 61
54 34 30 39
citations (top 5%), in 5 years after publication. WSZWS value (ratio of
to percentages of all worldwide publications in the top x% multiplied by
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Fig. 4. Changing proportion of closed and open access articles over time, 2001-2015.
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research output during the study period. The low overall
proportion of publications related to clinical trials also
points to a more worrying trend within radiation therapy
research. This concerns the level of evidence required to
integrate new processes of care and technologies into
treatment, which remains reliant on small-scale observa-
tional studies and, more recently, modeling studies (30, 31).
Although there are constraints to conducting phase 3 trials
in radiation therapy, increasing concerns about the value of
new innovations means that investment in trials is required
(public or private) to ensure new modalities are evaluated
with rigorous methods so as to enable cost-effectiveness
analyses to support their widespread implementation (32).
Of even greater concern is that once available in the market
following US Food and Drug Administration and European
Union approval, few phase 4 studies are subsequently un-
dertaken, even within centers that are early adopters of a
new technology (33). Pragmatic research designs, such as
multicenter observational cohort studies or nationally co-
ordinated coverage with evidence development schemes,
are alternative approaches that have been considered for
evaluating the effectiveness of treatment in the real-world
setting (31, 34).
A number of interesting observations are offered in
Table 3, which looks more closely at phase 1 to 3 trial
outputs from individual countries. European countries such
as the United Kingdom, The Netherlands, Sweden, and
Poland produce a much higher ratio of phase 3erelated trial
outputs relative to phase 2. India also demonstrated a
greater commitment to phase 3 relative to phase 2 trials,
compared with several high-income countries, where the
reverse trend was observed. For example, the United States,
Japan, and Italy had a significantly higher proportion of
phase 2 study outputs relative to phase 3. It is not clear why
such differences are apparent, but they may relate to eco-
nomic and cultural factors. For example, whether the
necessary infrastructure or funding is available to conduct
radiation therapy research trials may be one factor influ-
encing these figures. Countries may vary in the level ofevidence required by health care reimbursement organiza-
tions before they will routinely fund new technologies or
practices of care. In addition, organizations such as the US
Food and Drug Administration require demonstration of
safety, rather than efficacy, within phase 3 studies, before
approving new technologies, which has a downstream ef-
fect on the types of research evidence likely to be generated
before clinical adoption.
Although the United States was the largest contributor to
randomized controlled trial publications, the proportion of
its total radiation therapy research output devoted to ran-
domized controlled trials was significantly less than that in
other countries, such as India. This may reflect the recent
trend of pharmaceutical and medical technology companies
to conduct trials in countries where the personnel costs are
lower and where the large pool of potential research par-
ticipants can accelerate recruitment (35). There may be
many benefits that accrue to these countries from clinical
trials research, such as the opportunity for international
collaboration, investments in healthcare infrastructure, and
the redirection of research priorities toward locally relevant
and feasible interventions. However, concerns have also
been raised about whether there is adequate transparency
and oversight of human subjects in these countries, which
may have weak regulatory systems and limited experience
in research (35).
In this study we used 3 different citation scores based on
actual citation counts to rank countries on the quality and
importance of their published outputs. Although China,
Japan, France, and Germany were high-output countries in
terms of the number of research publications, their citation
performance was significantly lower than that of several
other countries that had lower research outputs (eg,
Denmark). Thismay be partly because their articles tended to
be published in low-impact journals or related to the lan-
guage in which theywere published. In that regard, a study of
the impact of publication language on citation frequency in
the scientific dental literature showed that articles published
in English had a 6-7 times higher chance of being cited than
articles published in German or French (36).
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countries are poorly cited. It is unclear whether this
relates to the perceived quality or level of interest in
research from these countries or the low impact factor of
the journals these studies are published in. This needs to
improve to encourage middle-income countries to become
more involved in radiation therapy research and influence
practices of care. If not, practices of care may risk
becoming regionally entrenched or influenced by a
few select countries in North America and Europe, which
could result in distinct knowledge gaps in the empirical
literature.
International collaboration is one mechanism by which
this situation can be improved and prevent unnecessary
duplication of research, to ensure the best available
evidence is used to drive radiation therapy practice. One
could consider a regional approach to identifying gaps in
the evidence base and undertake relevant clinical and
nonclinical studies, for example, through pre-existing
regional alliances such as the Regional Office for the
East Mediterranean and the Pan American Health
Organization. In addition, the International Atomic Energy
Association continues to support and coordinate multi-
national clinical radiation therapy trials (www-naweb.iaea.
org/nahu/ARBR/crp.html) that have impacted on clinical
practice (37).
Our analysis of open access articles demonstrates that
they are steadily increasing over time, representing nearly
40% of articles currently published in the WoS either as
gold or green open access. Although the overall citation
impact of more recent open access articles (2010-2012) is
higher than that of closed articles, this varies depending on
country of origin and the type of radiation therapy research
undertaken.
The present study must be considered in the context of
its strengths and limitations. The analysis has been under-
taken on an individual country basis, and findings with
respect to country outputs are potentially skewed depending
on the size (by population) and resources of individual
countries. However, this reflects the reality of their research
strengths and weaknesses. Outputs relative to each indi-
vidual country’s GDP and research impact have also been
presented. In addition, European countries that conduct a
number of collaborative multinational studies may seem to
produce comparatively less trial outputs when using frac-
tional counts compared with the United States, for instance.
A regionally based analysis may be one mechanism for
addressing this in the future. We have used citation fre-
quency as a proxy indicator for quality of research and
dissemination of scientific findings. However, a true eval-
uation of the scientific quality of publications cannot be
achieved without an independent and dedicated assessment
of their merit. Furthermore, citation frequency cannot
determine whether a publication changes practice and im-
proves population health (16).
We have not provided a detailed analysis of the factors
that have led to the observed trends and can onlyhypothesize potential reasons at this stage. The quantity of
research outputs may be affected by publication bias, with
failure of up to 20% to 30% of trials to report their
results (38). Equally excellent research may not be
published or published elsewhere. This will have an
impact on country-level integer and fractional counts, as
well as on potential underrepresentation of clinical research
outputs.
We have selected publications available in the WoS for
analysis, and it is therefore likely that some research output
in national language journals has not been included, which
could affect our results for country-level outputs. In
addition, as with any bibliometric evaluation, it is not
possible to guarantee inclusion of all relevant articles.
However, attempts to minimize this have been sought by
undertaking several iterations to develop the precision of
our search filters to ensure inclusion of articles that have a
relevant title word or Medical Subject Headings terms
specific for clinical and basic science articles in radiation
therapy. Although the WoS has selection criteria for the
inclusion of journals based on repute and citation, it is
unknown what proportion of low-quality “predatory” open
access articles is included and the impact this has had on
the estimations of total radiation therapy research output
(39). Finally, although our coding scheme for research
types was made as explicit as possible, it is possible that
some publications were miscategorized or that not all
publications could be categorized according to the selected
domains.Conclusions
To conclude, our findings provide a detailed analysis of
trends in radiation therapy research since 2001. Although
there has been a doubling of radiation therapy research
outputs over the study period, significant variation exists in
the research output of individual countries, with evidence
that radiation therapy research output is falling behind that
of other cancer-related research domains. Although LMICs
such as India, Iran, China, and Brazil continue to increase
their radiation therapy research output, this still lags behind
what is expected given their economic strength. Greater
support is required to develop the necessary infrastructure
to support high-quality research in LMICs that will
contribute to the development of the specialty overall but
allow the essential upscaling of radiation therapy resources
in these countries.
When considering the radiation therapy research types,
there is evidence of individual countries’ being committed
to particular domains that reflect national cultures and
economies. A major concern remains the very low pro-
portion of trial-related publications within radiation ther-
apy. This is an area that requires greater investment if we
are to try and establish the relevant evidence base to pro-
mote the implementation of the most cost-effective, high-
value care. In its absence, there will remain a lack of
Aggarwal et al. International Journal of Radiation Oncology  Biology  Physics778transparency as to the comparative benefits of innovations
relative to existing treatments, especially given that the
bulk of research focuses on clinical domains. To this end,
greater focus on quality of life studies is required: despite
the clinical predominance of most research output, few
articles considered these endpoints. In addition, it is un-
known what impact the slowing down of basic science
research outputs over the study period means in the long
term, with respect to identifying new pathways for
improving patient outcomes. Greater emphasis on health
services research would provide robust evidence on trans-
lating clinical evidence into practice. Finally, although
citation impacts do not necessarily reflect influences on
practices of care, they provide some understanding of the
degree of interest or quality of the article. Given differences
across countries, this may suggest that research outputs
from particular countries are considered to be of higher
quality and potentially have a greater impact on influencing
practices of care.
References
1. Eckhouse S, Lewison G, Sullivan R. Trends in the global funding and
activity of cancer research. Mol Oncol 2008;2:20-32.
2. Delaney GP, Barton MB. Evidence-based estimates of the demand for
radiotherapy. Clin Oncol (R Coll Radiol) 2015;27:70-76.
3. Shack L, Lu S, Weeks LA, et al. Determining the need and utilization
of radiotherapy in cancers of the breast, cervix, lung, prostate and
rectum: A population level study. Radiother Oncol 2017;122:152-158.
4. Borras JM, Lievens Y, Dunscombe P, et al. The optimal utilization
proportion of external beam radiotherapy in European countries: An
ESTRO-HERO analysis. Radiother Oncol 2015;116:38-44.
5. Aggarwal A, Lewison G, Idir S, et al. The state of lung cancer
research: A global analysis. J Thorac Oncol 2016;11:1040-1050.
6. Wallner PE, Steinberg ML, McBride WH, et al. A fork in the road:
Choosing the path of relevance. Int J Radiat Oncol Biol Phys 2015;92:
214-216.
7. Zietman A. The future of radiation oncology: The evolution, diversi-
fication, and survival of the specialty. Semin Radiat Oncol 2008;18:
207-213.
8. Lawler M, French D, Henderson R, et al. Shooting for the moon or
flying too near the sun? Crossing the value Rubicon in precision
cancer care. Public Health Genomics 2016;19:132-136.
9. Derrick GE, Pavone V. Democratising research evaluation: Achieving
greater public engagement with bibliometrics-informed peer review.
Sci Public Policy 2013;40:563-575.
10. Hood WW, Wilson CS. The literature of bibliometrics, scientometrics,
and informetrics. Scientometrics 2001;52:291.
11. Lewison G. Definition of cancer research: Journals, titles, abstracts or
keywords? DESIDOC J Libr Inform Technol 2011;31:333-339.
12. Lewison G. The definition and calibration of biomedical subfields.
Scientometrics 1999;46:529-537.
13. Waltman L, van Eck NJ. Field-normalized citation impact indicators
and the choice of an appropriate counting method. J Informetr 2015;9:
872-894.
14. Huffman MD, Baldridge A, Bloomfield GS, et al. Global cardiovas-
cular research output, citations, and collaborations: A time-trend,
bibliometric analysis (1999-2008). PloS One 2013;8:e83440.
15. Thelwall M. Interpreting correlations between citation counts and
other indicators. Scientometrics 2016;108:337-347.
16. Belter CW. Bibliometric indicators: Opportunities and limits. J Med
Libr Assoc 2015;103:219-221.17. Atun R, Jaffray DA, Barton MB, et al. Expanding global access to
radiotherapy. Lancet Oncol 2015;16:1153-1186.
18. Sullivan R, Purushotham A. Avoiding the zero sum game in global
cancer policy: Beyond 2011 UN high level summit. Eur J Cancer
2011;47:2375-2380.
19. Sullivan R, Ginsburg O, Aggarwal A. Research. In: Jemal A, editor.
The cancer atlas. 2nd ed. Atlanta, GA: American Cancer Society;
2015.
20. Rodin D, Aggarwal A, Lievens Y, et al. Balancing equity and
advancement: The role of health technology assessment in radio-
therapy resource allocation. Clin Oncol (R Coll Radiol) 2017;29:93-
98.
21. Jemal A, Ward EM, Johnson CJ, et al. Annual report to the nation on
the status of cancer, 1975-2014, featuring survival. J Natl Cancer Inst
2017;109:1-22.
22. Sanson-Fisher R, Bailey LJ, Aranda S, et al. Quality of life research: Is
there a difference in output between the major cancer types? Eur J
Cancer Care (Engl) 2010;19:714-720.
23. Hahn C, Kavanagh B, Bhatnagar A, et al. Choosing wisely: The
American Society for Radiation Oncology’s top 5 list. Pract Radiat
Oncol 2014;4:349-355.
24. Chen RC. Comparative effectiveness research in oncology: The prom-
ise, challenges, and opportunities. Semin Radiat Oncol 2014;24:1-4.
25. Lievens Y, Grau C. Health economics in radiation oncology:
Introducing the ESTRO HERO project. Radiother Oncol 2012;103:
109-112.
26. Larkin PJ, Murtagh F, Richardson H, et al. Collaboration: Securing a
future for palliative care research. Palliat Med 2016;30:709-710.
27. Kaasa S, Jordhoy MS, Haugen DF. Palliative care in Norway: A na-
tional public health model. J Pain Symptom Manage 2007;33:599-604.
28. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for
squamous-cell carcinoma of the head and neck. N Engl J Med 2006;
354:567-578.
29. Haviland JS, Owen JR, Dewar JA, et al. The UK Standardisation of
Breast Radiotherapy (START) trials of radiotherapy hypofractionation
for treatment of early breast cancer: 10-year follow-up results of two
randomised controlled trials. Lancet Oncol 2013;14:1086-1094.
30. Lievens Y, Borras JM, Grau C. Cost calculation: A necessary step
towards widespread adoption of advanced radiotherapy technology.
Acta Oncol 2015;54:1275-1281.
31. van Loon J, Grutters J, Macbeth F. Evaluation of novel radiotherapy tech-
nologies: What evidence is needed to assess their clinical and cost effec-
tiveness, and how should we get it? Lancet Oncol 2012;13:e169-e177.
32. Zietman A, Ibbott G. A clinical approach to technology assessment:
How do we and how should we choose the right treatment? Semin
Radiat Oncol 2012;22:11-17.
33. Lievens Y. Access to innovative radiotherapy: How to make it happen
from an economic perspective? Acta Oncol 2017;56:1353-1358.
34. Burock S, Meunier F, Lacombe D. How can innovative forms of
clinical research contribute to deliver affordable cancer care in an
evolving health care environment? Eur J Cancer 2013;49:2777-2783.
35. Glickman SW, McHutchison JG, Peterson ED, et al. Ethical and sci-
entific implications of the globalization of clinical research. N Engl J
Med 2009;360:816-823.
36. Poomkottayil D, Bornstein M, Sendi P. Lost in translation: The impact
of publication language on citation frequency in the scientific dental
literature. Swiss Med Wkly 2011;141:w13148.
37. Rosenblatt E, Jones G, Sur RK, et al. Adding external beam to intra-
luminal brachytherapy improves palliation in obstructive squamous
cell oesophageal cancer: A prospective multi-centre randomized trial
of the International Atomic Energy Agency. Radiother Oncol 2010;97:
488-494.
38. Jones CW, Handler L, Crowell KE, et al. Non-publication of large
randomized clinical trials: Cross sectional analysis. BMJ 2013;347:
f6104.
39. Shen C, Bjo¨rk BC. ‘Predatory’ open access: A longitudinal study of
article volumes and market characteristics. BMC Med 2015;13:230.
